Dufour, Florent
Silina, Linda
Neyret-Kahn, Hélène
Moreno-Vega, Aura
Krucker, Clémentine
Karboul, Narjesse
Dorland-Galliot, Marion
Maillé, Pascale
Chapeaublanc, Elodie
Allory, Yves
Stransky, Nicolas
Haegel, Hélène
Menguy, Thierry
Duong, Vanessa
Radvanyi, François
Bernard-Pierrot, Isabelle
Funding for this research was provided by:
EC | Horizon 2020 (666003)
Article History
Received: 2 May 2018
Revised: 18 December 2018
Accepted: 22 January 2019
First Online: 15 February 2019
Competing interests
: I.B.P., Y.A., N.S. and F.R. hold a patent describing TYRO3 as a therapeutic target for the treatment of cancer (patent publication WO/2010/031828), which has been licensed to ElsaLys Biotech. F.D., H.H., T.M., V.D., F.R. and I.B.P. hold a patent describing anti-TYRO3 antibodies (patent publication WO/2016/166348). The other authors have no competing interests.
: All patients provided informed consent, and the study was approved by the institutional review boards of the Henri Mondor, Foch and Institut Gustave Roussy Hospitals (Comité de Protection des Personnes de l’hôpital Henri Mondor, Comité de Protection des Personnes de Boulogne–Ambroise Paré, and Comité de Protection des Personnes de Bicêtre) in accordance with the French laws and the World Medical Association’s Declaration of Helsinki.<sup>5,11</sup> Mice were housed and cared for in accordance with the institutional guidelines of the French National Ethics Committee (<i>Ministère de l’Agriculture et de la Forêt, Direction de la Santé et de la Protection Animale</i>, Paris, France).
: This work was supported by <i>La Ligue Nationale Contre le Cancer</i>, through the funding of an accredited team (FR, IBP, FD, LS, HNK, AMV, CK, NK, MDG, EC, YA, NS, <i>Equipe labellisée</i>), by ANR Emergence Bio and by ElsaLys Biotech. This project also received funding from the European Union’s Horizon 2020 research and innovation program, under Marie Skłodowska-Curie grant agreement No. 666003.
: The microarray data are available from GEO (ExternalRef removed) under accession number GSE100025.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).